featured
Decitabine With Venetoclax for Newly Diagnosed Intensive Chemotherapy–Ineligible and Relapsed or Refractory AML
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Haematology